Chongqing Genrix Biopharmaceutical Co.,Ltd. Posted 388.2 Million Yuan Net Loss in First Half of 2023

Chongqing Genrix Biopharmaceutical Co.,Ltd. (重庆智翔金泰生物制药股份有限公司) (688443.SH) reported a net loss of 388.2 million yuan in the first half of 2023, widening 50.7% year-on-year.

Meanwhile, the company posted 132,804 yuan in revenue, down 70.6% year-on-year.

At the end of the reporting period, it had 4.1 billion yuan in total assets and 1 billion yuan in total liabilities, with a liability-to-asset ratio of 25.1%.